Summary
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
History
Ipsen was founded in 1929, initially focusing on the production of animal feed and Vitamin A supplements for human consumption. In the 70s, the company began to specialize in hormone replacement therapy to treat endocrine disorders. Following over a decade of research, Ipsen was the first company to develop a pituitary hormone replacement therapy, Ganiril. The company expanded further to develop innovative therapies in the areas of oncology, neurosciences and rare diseases.
Mission
To improve patients' lives.
Vision
Our vision is a world where everyone who is facing a life-threatening illness has access to the best personalized care in order to be able to live life to its fullest potential.
Key Team
Mr. Craig Marks (Vice-Pres of Investor Relations)
Mr. Francois Garnier (Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer)
Ms. Gwenan White (Exec. VP of Communications & Public Affairs)
Ms. Dominique Bery (Head of Nordics & Baltics)
Mr. Regis Mulot (Exec. VP & Chief HR Officer)
Dr. Yan Moore M.D. (Sr. VP & Head of Oncology Therapeutic Area)
Mr. Stephan Gagne (Head of New Tokyo Office)
Recognition and Awards
Ipsen has received numerous industry awards including the Prix Galien, Best New Medicine of the Year, Best Product of the Year, and Best Ophthalmic Medicine Manufacturer of the Year awards.
References
France 
